Table 1.
Baseline patient characteristics
| Combo arm (N = 33) | Fulv arm (N = 26) | Total (N = 59) | PEPI = 0 (N = 10) | |
|---|---|---|---|---|
| Age at consent (years) | ||||
| Median (range) | 63 (41, 78) | 61 (32, 83) | 63 (32, 83) | 66 (49, 76) |
| ECOG PS | ||||
| Median (range) | 0 (0, 1) | 0 (0, 2) | 0 (0, 2) | 0 (0, 1) |
| T stage | ||||
| T2 | 26 (78.8%) | 21 (80.8%) | 47 (79.7%) | 9 (90.0%) |
| T3 | 6 (18.2%) | 5 (19.2%) | 11 (18.6%) | 1 (10.0%) |
| T4 | 1 (3.0%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) |
| N stage | ||||
| NX | 1 (3.0%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) |
| N0 | 14 (42.4%) | 13 (50%) | 27 (45.8%) | 10 (100.0%) |
| N1 | 17 (51.5%) | 13 (50%) | 30 (50.8%) | 0 (0.0%) |
| N2 | 1 (3.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| ER/PR expression positivea | ||||
|
ER+ & PR− ER+ & PR+ |
3 (9.1%) 30 (90.9%) |
1 (3.8%) 25 (96.2%) |
4 (6.8) 55 (93.2%) |
2 (20.0%) 8 (80.0%) |
| % AR expression positivea | ||||
| N | 27 | 22 | 49 | 9 |
| Median (range) | 80 (10, 100) | 85 (10, 100) | 80 (10, 100) | 90 (10, 100) |
| Ki67 (%) | ||||
| N | 29 | 21 | 50 | 10 |
| Median (range) | 15 (1, 80) | 10 (1, 60) | 12 (1, 80) | 5 (1, 15) |
| Histology | ||||
| IDC | 25 (75.8%) | 20 (76.9%) | 45 (76.3%) | 5 (50.0%) |
| ILC | 5 (15.2%) | 6 (23.1%) | 11 (18.6%) | 4 (40.0%) |
| Other | 3 (9.1%) | 0 (0.0%) | 3 (5.1%) | 1 (10.0%) |
N is presented for variables with less than 59 observations.
aLab data were used to calculate AR, ER, and PR % Positive. ER and PR % Positive were replaced with clinical data when lab data were unavailable.